Skip to content

Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate Reconstruction

Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate Reconstruction : an International Multicenter Pooled Analysis

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04108117
Acronym
SORI
Enrollment
659
Registered
2019-09-27
Start date
2020-05-14
Completion date
2022-05-18
Last updated
2023-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

BRCA1 Mutation, BRCA2 Mutation, Breast Cancer, Breast Neoplasms, Postoperative Complications, Recurrence, Surgery, Surgery--Complications

Keywords

Robotic mastectomy, Breast neoplasms, Postoperative complications, Recurrence, Prognosis, Survivals, Nipple sparing mastectomy, Immediate reconstruction

Brief summary

Robotic mastectomy with immediate reconstruction was introduced by Toesca et al. in 2015. Since then, several studies have reported the safety and feasibility of robotic nipple-sparing mastectomy with immediate reconstruction. However, most studies were conducted by single centers and had small samples. Furthermore, there is a lack of studies comparing surgical and oncologic outcomes between robotic nipple-sparing mastectomy and conventional nipple-sparing mastectomy. For this reason, this study evaluates surgical and oncologic outcomes of robotic nipple-sparing mastectomy with immediate reconstruction using international multi-center data.

Detailed description

This study is an international multi-center pooled analysis using prospective and retrospective studies to evaluate surgical and oncologic outcomes of robotic nipple-sparing mastectomy with immediate reconstruction. Raw data for robotic or conventional nipple-sparing mastectomy from Severance Hospital, Samsung Medical Center, the European Institute of Oncology, Changhua Christian Hospital, and Gustave Roussy is collected. Among them, Severance Hospital takes the lead at performing analysis from the data. Storage and disposal of patients' records are managed by each researcher. In the analysis process, although the collaborators can request records from Severance Hospital if necessary, they are only supposed to be provided computerized data which were originally clinical data from patients who already ended treatments. In this case, individual identifying data and medical records are not shown. Clinicopathologic variables including operation times, hospital stay, medical history, smoking history, family history, BMI, menopausal status, specimen weight, TNM stage, grade, histological type, estrogen receptor, progesterone receptor, HER2, Ki 67, and perivascular involvement are analyzed. Postoperative complications within 30 days are collected and classified by the Clavien-Dindo grade. Locoregional recurrence-free survival and local and systemic recurrences are examined. Patients whose data have been retrospective for at least one month are to be examined. Patient's and surgeon's satisfaction using Breast Q is evaluated. Categorical variables are examined using the chi-square test or Fisher's exact test if indicated. Continuous variables are examined using the independent t-test or ANOVA if indicated. The estimated sample size from the four institutions is about 300 cases for robotic nipple-sparing mastectomy and matched cases for conventional nipple-sparing mastectomy. Propensity matching analysis is applied to reduce confounding factors.

Interventions

PROCEDURERobotic nipple sparing mastectomy

Robotic nipple sparing mastectomy means nipple sparing mastectomy performed using robotic surgical systems.

Sponsors

European Institute of Oncology
CollaboratorOTHER
Changhua Christian Hospital
CollaboratorOTHER
Samsung Medical Center
CollaboratorOTHER
Severance Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Healthy volunteers
Yes

Inclusion criteria

* Women who underwent nipple sparing mastectomy and immediate reconstruction * Women with early breast cancer * Women with germline BRCA 1/2 mutation or germline mutations in genetic susceptibility genes * Women with interstitial mastopathy * Women with risk-reducing mastectomy or contralateral mastectomy

Exclusion criteria

* Male patients * Women with stage IV disease at diagnosis * Women who underwent previous breast cancer surgery * Women who received prior radiotherapy for the ipsilateral breast

Design outcomes

Primary

MeasureTime frameDescription
Postoperative complication rates in 30 daysPostoperative 30 daysPostoperative complication rates are calculated as total number of postoperative complication cases per total operation cases.
Clavien-Dindo grade of postoperative complicationsPostoperative 30 daysClavien-Dindo grade of postoperative complications is evaluated. The highest grade of postoperative complications are used for the analysis.
Nipple necrosis ratesPostoperative 30 daysNipple necrosis rates are calculated as number of total nipple necrosis cases per total operation cases.
Recurrence free survival (RFS)Postoperative 5 yearsEvents of RFS includes locoregional recurrence, distant recurrence, and death. Contralateral breast cancer and second primary malignancy are considered to be censored data.

Secondary

MeasureTime frameDescription
Operation timesTime during operationMastectomy time or reconstruction time
Locoregional recurrence-free survival (LRFS)Postoperative 5 yearsIn breast tumor recurrences (IBTR), regional recurrences including axillary, internal mammary, or supraclavicular lymph node recurrences, and death without any cause are events of locoregional recurrence-free survival. Five year LRFS is measured. Distant metastasis, contralateral breast cancer and second primary malignancy are considered to be censored data.

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 11, 2026